A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation
Latest Information Update: 03 Jan 2022
Price :
$35 *
At a glance
- Drugs Clopidogrel (Primary) ; Aspirin
- Indications Myocardial infarction; Stroke; Thromboembolism; Vascular disorders
- Focus Registrational; Therapeutic Use
- Acronyms ACTIVE; ACTIVE-A
- Sponsors Sanofi
- 15 Nov 2021 Results investigating the association of NT-proBNP with heart rhythm and cardiovascular (CV) events in patients with AF without oral anticoagulation presented at the American Heart Association Scientific Sessions 2021
- 04 Aug 2019 Results (n=962) of post-hoc analysis assessing thrombooembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment of this and ACTIVE-W trial published in the European Heart Journal
- 05 Apr 2011 Combined results from this study and the AVERROES study presented at the 60th Annual Scientific Session of the American College of Cardiology.